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a  b  s  t  r  a  c  t
Natural  substances,  particularly  medicinal  plants  and  their  extracts,  are  still  today  intended  as  source
for new  Active  Pharmaceutical  Ingredients  (APIs).  Alternatively  they  can  be  validly  employed  to prepare
medicines,  food  supplements  or medical  devices.  The  most  adopted  analytical  approach  used  to  verify
quality  of natural  substances  like  medicinal  plants  is  based  still  today  on  the  traditional  quantitative
determination  of  marker  compounds  and/or  active  ingredients,  besides  the  acquisition  of a  ﬁngerprint
by  TLC,  NIR, HPLC,  GC.
Here  a new  analytical  approach  based  on  untargeted  metabolomic  ﬁngerprinting  by means  of  Mass
Spectrometry  (MS)  to verify  the  quality  of grinTuss  adulti  syrup,  a  complex  products  based  on  medicinal
plants,  is  proposed.  Recently,  untargeted  metabolomic  has  been  successfully  applied  to  assess  quality  of
natural substances,  plant  extracts,  as well  as  corresponding  formulated  products,  being  the complexity  a
resource  but  not  necessarily  a limit.  The  untargeted  metabolomic  ﬁngerprinting  includes  the monitoring
of  the  main  constituents,  giving  weighted  relevance  to the most  abundant  ones,  but also  considering
minor  components,  that might  be notable  in view  of an  integrated  – often  synergistic  –  effect  on  the
biological  system.Two  different  years  of  production  were  investigated.  The  collected  samples  were  analyzed  by Flow
Injection  ElectroSpray  Ionization  Mass  Spectrometry  Analysis  (FIA-ESI-MS)  and  a suitable  data  processing
procedure  was developed  to transform  the  MS  spectra  into  robust  ﬁngerprints.  Multivariate  Statistical
Process  Control  (MSPC)  was  applied  in order  to obtain  multivariate  control  charts  that  were  validated  to
prove the effectiveness  of  the  proposed  method.
©  2016  The  Authors.  Published  by Elsevier  B.V. This  is  an open  access  article  under  the  CC BY  license. Introduction
Natural substances as medicinal plants have been used since
ncient times in the folk medicine for treating a broad range of dis-
ases. Although the last decade has witnessed a marked growth
n the market of plant-based natural products, their high com-
lexity in terms of composition still makes a challenging task the
uarantee of quality, efﬁcacy and safety requirements [1,2]. In gen-
ral, quality control of natural substances as medicinal plants is
ased on three important pharmacopoeias deﬁnitions: identity,
 Selected paper from conference of Recent Development in Pharmaceutical Anal-
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purity and content or assay. To prove identity and purity, criteria
such as type of preparation sensory properties, physical constants,
contaminants, moisture, ash content and solvent residues have to
be checked. Content or assay is the most difﬁcult area of quality con-
trol to perform, since in most natural substances as medicinal plants
and corresponding formulated products the active constituents are
not known. When the active constituents (e.g. sennosides in Senna)
or markers (e.g. alkylamides in Echinacea) are known, a vast array
of modern chemical analytical methods such as Ultraviolet/Visible
spectroscopy (UV/Vis), Thin Layer Chromatography (TLC), High-
Performance Liquid Chromatography (HPLC), Gas Chromatography
(GC), Mass Spectrometry (MS), or a combination of GC or LC and MS,
can be employed [3]. In all other cases, where no active constituent
or marker can be deﬁned, it seems to be necessary to determine
the most of the chemical constituents in order to ensure the reli-
ability and repeatability of pharmacological and clinical research,
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Table  1
Workﬂow for developing an analytical method based on metabolomics.
STEP DEFINITION
Pre-processing Generic term for methods to go from raw instrumental data to clean data for processing.
Pre-treatment Transforming the clean data to make them ready for data processing.
Processing Data analysis (PCA, PLS, etc).
Post-processing Transforming the results from the processing for interpretation and visualization (e.g. antilog).
Validation All the activities aimed at assuring the quality of the conclusion drawn from the data analysis.
Interpretation Hypothesis generation, visualization of the data.
Table 2
Quali-quantitative composition of the ‘bad’ quality samples.
Entry Composition
1 Honey (81%), deionized water (19%)
2  Cane sugar (50%), honey (25%), deionized water (25%)
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(0.5%), Plantain (Plantago Lanceolata) freeze drie
freeze dried extract (0.2%), plantain mother tinc
nd to enhance product quality control. By deﬁnition, a chromato-
raphic ﬁngerprint of natural substances as medicinal plants and
orresponding formulated products refers to the proﬁles which can
llustrate the speciﬁc properties of raw materials, semi-ﬁnished
roducts and ﬁnished products after appropriate processing, and
an be obtained by suitable analytical techniques [4–6].
In recent years, new analytical platforms based on Nuclear Mag-
etic Resonance (NMR) or Mass Spectrometry (MS) have been
uccessfully applied to determine the composition of natural com-
lex products based on medicinal plants in terms of structurally
ifferent compounds such as primary and secondary metabolites
7]. By means of the metabolomic ﬁngerprinting is therefore possi-
le to bridge the lack of characterization of natural substances such
s medicinal plants, extracts, fractions and formulations compris-
ng them, that so can be characterized by no more than a reduced set
f components but from a very large set of metabolites (hundreds)
ypical for each natural product.
Two complementary approaches are currently available for the
nvestigation of natural complex products by metabolomics: the
argeted and the untargeted approach [8]. Both of them are required
o achieve the complete characterization of natural products. In
articular, while targeted metabolomic is aimed to the quantitative
etermination of speciﬁc sets of metabolites (usually 5–10 metabo-
ites for each class under investigation), the untargeted approach
s aimed to obtain a broad picture of the whole metabolome by
etecting as many metabolites as possible (usually hundreds of
etabolites), without necessarily identifying nor quantifying spe-
iﬁc compounds [9].
By targeted metabolomics methods it is possible to perform
uality control quantifying known metabolites. By untargeted
ethods quality control is evaluated taking a product ﬁngerprint
ncluding both known and unknown metabolites and classifying
t as ‘good’ or ‘poor’ quality product, based on the comparison of
he obtained ﬁngerprint with those of ‘good’ samples. In our study
he good samples are approved batches prepared according to the
ood Manufacturing Practice (GMP), using controlled raw materi-
ls, through a validated production process constantly veriﬁed by
onventional approaches.
Untargeted metabolomic ﬁngerprinting is a high throughput
ethod to perform global analysis of complex mixtures and pro-
ides a fast and accurate method for sample classiﬁcation.
Starting from the general assumption that several metabolites
ay  contribute to the activity of natural complex products, inhis study we investigated the possibility to extract useful infor-
ation concerning the biological uniformity or diversity among
ifferent batches of the production supply chain, considering thechrysum Italicum) freeze dried extract
act (0.2%), Gumweed (Grindelia Robusta)
0.7%).
whole formulation rather than few and well-selected compounds
of the formulated natural complex products. In this context, the
Flow Injection ElectroSpray Ionization Mass Spectrometry Analy-
sis (FIA-ESI-MS) of the whole formulated natural complex products
represents a valuable alternative to the traditional reductionist
approach, providing big data generation in high-throughput fash-
ion by avoiding any prior chromatographic steps [6] although
suffering of instrumental signal ﬂuctuation and ion suppression
issues.
Based on these considerations, this study was  focused to over-
come the problems related to untargeted mass spectrometry-based
metabolomic analysis such as reproducibility in order to obtain a
validated quality control protocol for monitoring the batch-quality
of grinTuss adulti syrup by Multivariate Statistical Process Control
(MSPC). More speciﬁcally, the adopted workﬂow was based on
the preliminary sample preparation followed by its direct infusion
through ﬂow injection into a mass spectrometer endowed with an
ESI interface and an ion trap as analyzer, to generate a ﬁngerprint
useful for assessing the quality of the formulated natural com-
plex product. About this, a speciﬁc data processing procedure was
developed to allow the calculation of a robust ﬁngerprint useful for
building multivariate control charts. The key points of the proposed
approach were the use of the so called Golden Standard (GS) sam-
ple to guarantee the comparison of samples analyzed in different
experimental sessions and the introduction of a robust method for
peak list matching and data normalization.
Actually, regulatory guidelines for the development and val-
idation of methods based on untargeted metabolomics are not
available [10], but researchers members of the Metabolome Stan-
dard Initiative (MSI) proposed the workﬂow reported in Table 1
as good practice for developing analytical methods based on
metabolomics [11]. We  decided to follow the reported workﬂow
in the development of our method for quality control.
2. Experimental
2.1. Experimental design
Two  different years of production were monitored collecting 24
samples, each one corresponding to a different batch of produc-
tion. In particular, the last 6 batches produced as test set were used
while the remaining 18 batches were employed to build the control
charts. Moreover, for the test set 3 samples were expressly pro-
duced in laboratory by using a deliberately incorrect composition
of grinTuss adulti syrup in order to reproduce the proﬁle of possible
batches deriving from production errors and were therefore used
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Fig. 1. GrinTuss adulti syrup ﬁngerprint mass spectrum background subtracted.
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Fig. 2. PCA score scatter plot of the collected samples coloured according to the
experimental session (R2 = 0.75); stars were used to indicate the GS while circles
the  samples.
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Fig. 3. PCA score scatter plot of the collected samples after data processing coloured
2
soluble. The use of other solvents, including water, methanol or
their mixtures, led to abnormal peak shape not easy to integrate ins model of ‘bad’ quality batches (Table 2). In particular, the ‘bad’
uality samples were obtained by preparing grinTuss adulti syrup
ugary compositions without freeze-dried extracts (Table 2, entry
 and 2) and a grinTuss adulti syrup formulation with similar rela-
ive ratios of sugary components and freeze-dried extracts (Table 2,
ntry 3).
The 18 samples used as training set to build the control
harts represented the proﬁle of ‘good’ quality batches since they
ere prepared according to the optimized manufacturing protocol
according to GMP) and submitted to the standardized conven-
ional quality control operations. Furthermore, GS was  selected as
n approved batch of the production supply chain exerting the same
uali-quantitative proﬁle of the ‘good’ quality samples. A prelimi-
ary data analysis of the training set based on Principal Component
nalysis (PCA) allowed us to identify the GS to use in the experi-
ental sessions. Thus the GS was selected as the closed sample to
he centre of the PCA score space in order to be the most repre-
entative sample of the training set. All the samples were stored at
80 ◦C prior to perform the analytical session to avoid bias due to
he conservation of the GS. Our previous studies on the stability of
he product proved that no relevant modiﬁcations in the metabolic
ontent must be expected during the conservation. However, mod-
ﬁcations were highlighted between fresh and frozen samples and,
s a consequence, all the samples were frozen before the analysis.according to the experimental session (R = 0.52); stars were used to indicate the GS
while circles the samples.
2.2. Chemical and reagents
Absolute ethanol 99.8% and pure methanol 99.9% were pur-
chased from Sigma-Aldrich. Ultrahigh puriﬁed water used in this
study was prepared in a PurelabUltra water puriﬁcation system
(ELGA, UK). The batches of grinTuss adulti syrup were produced
by Aboca SpA (Sansepolcro, Italy). GrinTuss adulti syrup is a nat-
ural complex product consisting mainly of fraction extracted from
Elichrysum Italicum (top ﬂowered head), Plantago Lanceolata (leaf),
Grindelia Robusta (top ﬂowered head) and honey. Three batches
were appositely produced in laboratory according to the composi-
tion reported in Table 2.
2.3. Sample preparation
0.5 g of each sample are extracted with 100 mL of ethanol/water
50:50 (w/w) in ultrasonic bath for 20 min. The solution obtained,
after ﬁltration on 0.45 m cellulose acetate syringe ﬁlter, was
transferred in a vial and analyzed. To achieve a signal intensity
of 105–106, the obtained solution was  analyzed without further
dilution.
The sample, treated with ethanol/water 50:50 (w/w), resultedthe data pre-processing step.
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.4. FIA-ESI-MS conditions
FIA-ESI-MS analysis was carried out in a HPLC 1100 Series (Agi-
ent Technologies INC., Santa Clara, CA) system equipped with a
acuum degasser, a binary pump, a Peltier thermostated autosam-
ler at 10 ◦C and the efﬂuent was analyzed by an ion trap mass
pectrometer SL series equipped with an ESI interface (Agilent
echnologies INC., Santa Clara, CA) operating in negative ion
ode. Without any chromatographic separation (being the column
eplaced with an adapter connecting the capillaries between the
njector and the interface) the ﬂow rate was 0.2 mL/min and an
njector volume of 5 L. The instrumental parameters were opti-
ized in wide mode, with a width from 50 to 1500 m/z. The ion
rap mass spectrometer optimized parameters were set as follows:
ntrance Capillary Voltage +4500 V; End Plate Offset −500 V; Dry
as ﬂow 8 L/min; Dry Temperature 350 ◦C; Skimmer −33.1 V; Cap-
llary Exit −111.5 V; Oct 1 DC −12.00 V; Oct RF 300.0 Vpp; Oct 2
C −1.70 V; Lens 1 5.5 V; Lens 2 57.2 V; Trap Drive 45.2. The ESI
nterface nebulizer gas pressure was set at 20 psi.
The mobile phase consisted of pure methanol (A) and ultrapure
ater (B) according to the following elution: 0–5 min  A/B 50:50
v/v). Before injecting a new sample, a system equilibration time of
0 min  was required, using as eluting solvent A/B 50:50 (v/v). Dif-
erent mobile phases were tested but the mixture methanol/water
0:50 (v/v) was ﬁnally chosen as led to the best analytical perfor-
ance. In absence of the column, the introduction of the sample
sing the HPLC pump by ﬂow injection create a peak that eluted
etween 0.05 min  and 5.0 min, the time required to the signal to
eturn to the baseline.
.5. FIA-ESI-MS analysis
The collected samples were analyzed in 11 different analytical
essions, the test set corresponding to the last session. In all the
essions, experiments were run in triple randomizing the run order:
 golden standards were run at the beginning, in the middle and
t the end of each session, while a blank run was performed after
ach sample. All the sessions and runs were evaluated, also, to check
ntra-laboratory repeatability of the method between two different
nalysts.+ of the samples of the training set (from C1 to C18) while in blue the DModX+ of
2.6. Data processing
Several sources of variation could affect the data sets produced
by FIA-ESI-MS with the result to cover the biological diversity of
the collected samples. The main sources of variability were iden-
tiﬁed in the sample collection and preparation, analytical session
and biological diversity of the samples. So it was applied speciﬁc
procedures for reducing the effect of these source of variability in
order to produce ﬁngerprints and, then, multivariate control charts
assessing only to the biological variability. More speciﬁcally, the
variability due to sample collection and preparation was reduced
by training the operator while variations due to the experimen-
tal platform were limited using randomized run sequences with
GS and blank samples, calibration procedures for the detector and
the application of suitable tools for data pre-processing and pre-
treatment.
2.6.1. Data pre-processing
The data acquired were peak picked and, within each
experimental session, the background was subtracted to the cor-
responding sample using Subtract View Spectrum as Background
routine of the Data Analysis software (trap version 3.3, Bruker
Daltonik GmbH). A typical grinTuss adulti syrup ﬁngerprint mass
spectrum bachground subtracted in Fig. 1 is reported.
As a result, for each sample a peak list with m/z  values and the
corresponding peak intensity was generated.
2.6.2. Data pre-treatment: peak list matching and data
normalization
Since the analysis of the collected samples can produce peak lists
where the same metabolite could be present with a different value
of m/z  depending on the mass accuracy and resolution of the mass
spectrometer, a data matching procedure was applied to match cor-
responding peaks in the obtained peak lists. The result of the peak
list matching was a data table having the sample representation
in terms of peak intensity in rows and columns corresponding to
the m/z  of the detected metabolites. Peaks detected in different
samples were matched through the calculation of a suitable match
score (Eq. (1)) that was  deﬁned as:
scoreij = 1 −
|m/zi − m/zmasterj|
d
(1)
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here m/zi is the m/z  value for the peak i to be matched, m/zmasterj
s the m/z  value of the peak j of the master peak list and d the m/z
olerance. The master peak list was deﬁned as the list containing all
he detected peaks represented by the mean m/z  values calculated
or the samples showing that peak. Due to the m/z  resolution of
he mass detector used in this study, d = 0.8 was considered. The
lgorithm used for matching the peaks takes one peak from a peak
ist at a time and matches the peak to either the best matching
eak of the master peak list or appends a new peak to the master
eak list, if matching is not found for the peak. The best matching
s calculated on the basis of the match score while the m/z  value
f the master peak list is updated by mean calculation if matching
s found. The algorithm can be summarized as the following 4 step
rocedure:
 the master peak list is initially set to the peak list of the ﬁrst
sample;
 the peak list of the second sample is compared with the master
peak list; for each peak of the peak list the match score is calcu-
lated and, on the basis of the best score, each peak is matched to
a peak of the master peak list or added as new peak of the master
peak list if the score is zero;
 the m/z  values of the master peak list are updated on the basis of
the matched peaks;
 iterate steps 2 and 3 including the other samples one at time.
The ﬁnal result of the procedure is the master peak list and the
ata table containing all matched samples. In case of new samples
o be matched, the step 2 of the proposed algorithm is iteratively
sed without the updating step of the master peak list. The peaks
howing match score equal to zero are excluded from the data table
nd singularly investigated to highlight potential contaminants.
The master peak list could reﬂect the order of the samples used
uring the peak list matching procedure. For this reason, it was
pplied the following strategy for deﬁning the order of the samples
o use. A ﬁrst data matching was performed by using a m/z  tolerance
qual to 2. The obtained data table was centred on the mean and
ubmitted to PCA considering 3 principal components. In this way
 ranking for the samples based on the increasing distance to the
entre of the PCA score space was deﬁned. The sample closest to
he centre was used as starting point for peak list matching (step 1)
hile the obtained ranking deﬁned the order to use. The procedure
as repeated until convergence of the list corresponding to the
anking.
Also, the resulting data table may  contain empty gaps, in case a
atching peak was not found in some of the peak lists. To reduce
he number of gaps in the resulting data table and then to limit
he possible inﬂuence of missing data in the control charts, only
he metabolites detected in more than 90% of the samples in the
alculation of the master peak list were selected.
The master peak list was built considering only the GS included
n the training set. As a result, a master list composed of 529 peaks
as obtained.
For data normalization, the following expression (Eq. (2)) for the
ntensity IˆikJ in the matched peak list was considered:
ikJ = ˛kIiJ + ıikJ (2)
here IiJ is the intensity of the metabolite i in the sample J, ˛k
s a factor depending on the experimental run k and ıikJ is the
ackground random noise. The effects of the random noise were
educed by calculating the median of the 3 replicates of each sam-
le within the same experimental session while the effects of ˛k
ere taken into account applying Median Fold Change normaliza-
ion (MFC normalization) on the GS injections. Since the GS was
un in all the different experimental sessions and in three differ-Biomedical Analysis 126 (2016) 156–162
ent times within the same experimental session, it was possible
to estimate ˛k and then to normalize the data following a two
steps procedure: chosen a run of the GS as reference, ﬁrstly the fold
change (i.e. the ratio between the intensity measured for a speciﬁc
run of the GS and that of the reference) between GS and reference
is calculated for each variable of the master peak list and secondly
the median of the all fold changes is calculated. The median is then
used to normalise all the samples nearest to the considered GS.  The
procedure is repeated for each run of the GS.
It should be noted that the choice of the reference does not affect
the performance of the obtained control charts. Indeed, different
choices produce data sets with a different factor scale without mod-
iﬁcation of the topology of the latent space.
2.7. Data analysis
After peak list matching, median of the replicates and MFC  nor-
malization each sample resulted to be described by the same set
of variables. The obtained representation was submitted to multi-
variate data analysis. PCA is a well-known multivariate technique
useful for exploratory data analysis and for data compression [12].
For quality control purposes, PCA can be successfully applied to
summarize the features characterising batches of ‘good’ quality in
order to discover batches of ‘poor’ quality when compared to the
former by the PCA model. About this, latent variables derived by
PCA, the residuals of the model or suitable combinations of scores
and residuals such as DModX+ (i.e. the Distance to the Model aug-
mented with a term measuring how far outside the acceptable
model domain the projection of the observation falls) can be dis-
played by control charts [13–15]. This enables the speciﬁcation of
multivariate control limits, rather than control limits connected
to univariate control charts of the single measured variables. The
use of such multivariate control charts helps ensure that the prod-
uct is manufactured with good quality attributes, according to all
the monitored variables. In this study, the control charts based on
the DModX+ parameter showed the most interesting behaviour,
discovering ‘bad’ batches and correctly classifying “good” batches.
Data were mean centred and Pareto scaled prior to perform data
analysis.
Multivariate statistical data analysis was performed by SIMCA
13 (Umetrics, Umea, Sweden) while data pre-treatment was
applied by R-functions developed within the platform R 3.0.2 (R
Foundation for Statistical Computing).
3. Results
The data set resulted to be composed of 105 analytical runs (24
samples × 3 replicates + 33 GS runs) and 529 m/z  variables. To high-
light the effects of the proposed procedure for data pre-treatment,
we ﬁrstly report the investigation of the data set prior to calculate
the median of the replicates and to apply data normalization. The
obtained PCA model showed 2 principal components, R2 = 0.75 and
Q2CV7-folds = 0.68. The score scatter plot is reported in Fig. 2. It is pos-
sible to observe how the GS sample runs span a large space in the
plot if compared with the region occupied by the other samples (the
variance of the X-block related to GS is 0.85 times that of the other
samples). In other words, since the GS sample runs correspond to
the same sample it can be afﬁrmed that the variability produced in
the data by the different experimental sessions has the same mag-
nitude of the variability arising from the biological diversity of the
samples.To reduce the effects of the experimental session, the pre-
treatment procedure described above was  applied. After the
calculation of the median of the replicates and MFC  normalization
on the GS, the PCA model showed 2 principal components, R2 = 0.52
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nd Q2CV7-folds = 0.25. The score scatter plot is shown in Fig. 3. In this
ase the GS runs are more closed to each other than in the previous
ase and the effects due to the experimental session are reduced
the variance of the X-block related to GS is 0.15 times that of the
ther samples).
The control charts for MSPC where built on the basis of the PCA
odel of the data set composed of the 18 samples representing
atches of ‘good’ quality. The PCA model showed 3 principal com-
onents, R2 = 0.63 and Q2CV7-folds = 0.26. The test set composed of
he last 6 produced batches were projected on the PCA model in
rder to obtain the parameters useful to evaluate the compliance
ith the ‘good’ batches. On the basis of the DModX+ control chart
ith a control limit equal to 95%, 3 batches resulted to be compliant
hile 3 batches resulted very different. The batches not compliant
ere those batches expressly produced in laboratory as batches of
bad’ quality and then, the control chart resulted to correctly high-
ight ‘bad’ batches while the batches resulted to be compliant were
atches of ‘good’ quality. Fig. 4 reports the DModX+ control chart.
. Discussion
Analytical variability in automated Direct Infusion Mass Spec-
rometry (DIMS) metabolomic analysis, as FIA-ESI-MS, is a
ell-known issues [16]. DIMS-based untargeted metabolomics
easures many hundred of metabolites in a single experiment and
any researcher are still working to reduce within-experiment
nalytical variation, particularly true for large scale multi batches
nalysis. For this reason the use of a metabolomic analysis for
uality evaluation of complex natural products batches through
ifferent years of production is a challenging task. Many studies
re present in the ﬁeld of metabolomics and some ‘best practice’
rocedures are reported. Among these the constancy of the ion
umbers between different batches can be evaluated. Also a robust
uality control (CQ) sample, replicate measurement, blank sam-
les can be introduced in the metabolomic workﬂow to evaluate
he instrumental performance [17].
In our study we propose a new method for reducing the effect
f the different analytical sessions on the data in order to obtain
ontrol charts where the biological source of variation can be easily
ighlighted. For this reason, we introduced the use of GS samples in
ach experimental session and a suitable data pre-treatment based
n the information collected through the analysis of the GS sam-
les in the different analytical sessions. Speciﬁcally, locked master
eak list was used for matching the samples to reduce the effect of
he decay of the performance of the ion source during the experi-
ent, median of the replicates was applied to remove the effect of
he random noise while data normalization based on Median Fold
hange was performed on the GS to estimate the factor ˛k spec-
fying the response of the detector for each run. As a result, the
ode of action of the proposed method can be clearly understood
aken into account their relationships with the expression used for
he intensity of the detected peaks. On the other hand, other meth-
ds capable to remove the effects of the experimental session on
he collected data could be used. We  recognized two  main families
f techniques: techniques based on multivariate approaches and
echniques based on the analysis of each single detected metabo-
ite. The former use PLS-DA or PCA to model the variance due to
he experimental session and removes the related score-loading
roduct from the collected data while the latter use ANOVA or its
ariations to remove the effects due to the different analytical ses-
ion. We  are investigating these alternative approaches in order
o test their performance in a production environment since they
ere developed only for research aims. Artefacts and over-ﬁtting
ould be produced by these techniques and their mode of action
n the detected signals are often difﬁcult to understand. Then, inBiomedical Analysis 126 (2016) 156–162 161
this study we  preferred to use the described approach instead of
other methods to avoid over-ﬁtting and to have a robust method
to implement in quality control.
The multivariate control charts used in this study investigated
the correlation structures underlying the measured variables. This
allowed us to discover complex structures within the samples that
cannot be highlighted by classical univariate approach. Anyway,
univariate data analysis based on classical control charts was imple-
mented in order to disclose signiﬁcant variations in each single
variable. Indeed, multivariate and univariate data analysis must be
considered as complementary approaches. In this study, the uni-
variate control charts conﬁrmed the conclusion of the multivariate
control charts. However, it should be noted that in the multivari-
ate case the DModX+ control chart is able to summarize the effects
included in more than 500 univariate control charts. Also, the part
of the peak list of the new samples to be investigated not included in
the master peak list must be analyzed to evaluate the risk of poor
quality batches. Usually, the number of these peak is very small
and a manual check is not time consuming. In our study the peaks
being metabolites that were not included in the master peak list
were not more than 15, corresponding to the 2% of the total num-
ber of recorded signals in the worst case while in more than the 80%
of the samples we did not ﬁnd metabolites that were not included
in the master peak list.
In this study, we  used a multinormal distribution to describe
the distribution of the ‘good’ batches in the latent space of the PCA
model. In case of more complex distributions, it is possible to apply
the kernel density estimation method to evaluate the distribution
of the training set samples in the latent space and the distribution
of the residuals.
The proposed method, based on the GS and on the master peak
list used for peak matching, depends on the sample selected as GS.
However, since the collected samples correspond to the same prod-
uct, in principle it is possible to choose a new GS to replace the old
one having approximately the same number of peaks of the master
peak list. The master peak list should be updated by excluding the
peaks not found in the new GS, if one want to re-use all the samples
collected in the past while data normalization can be recalculated
on the new GS, once the new GS is run together the old GS.
In a routine quality control metabolomic analysis, the following
workﬂow can be used as Standard Operating Procedure (SOP) for
monitoring batches quality:
© acquisition of the new sample in triple with related GS and blank
samples randomizing the experimental runs;
© matching of the replicates to the master peak list;
© normalize the data;
© calculation of the median of the replicates;
© projection of the sample on the control charts;
© evaluation of the compliance on the basis of the control charts
(PCA scores, DModX+);
© update of the control charts with the compliant samples; if the
sample is not compliant to the good quality batches, it is neces-
sary to proceed to checkout and only after more insights if the
batch meets the quality requirements the control charts can be
updated.
5. Conclusions
Nowadays, metabolomic ﬁngerprinting can be considered as
the evolution of the consolidated approaches for analyzing well-
selected marker compounds for quality evaluation of complex
products, based on natural substances as medicinal plants. It is
quick scan, selective, speciﬁc, and it has been used to discriminate
different plant samples [18] as well as multi-component ﬁnished
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roducts [19]. By means of untargeted metabolomics a ﬁngerprint
f the product can be obtained; therefore it provides tools for qual-
ty control more accurate than traditional methods.
The metabolomic approach is widely employed in medicine and
iology, due to the high amount of molecular information that can
e gain by it. However the application of metabolomics based-
alidated methods to quality control of complex natural products
s relatively unexplored. Following the workﬂow of MSI  it was pos-
ible to reach the goal of having a multivariate statistical method,
seful to assess batch compliance as well as to monitor the produc-
ion chain.
The robust analytical protocol developed for evaluating the
omplex product composition, offers a criterion based on the appli-
ation of multivariate control charts useful to evaluate globally
he complex products quality compliance. By this way the main-
enance of the biological properties batch to batch can be assured
nd, consequently, their efﬁcacy and safety.
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